HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc., announced the signing of a term sheet with Universal Capital, LLC for a $7.8 million debt facility. This financing is intended to provide acquisition capital to initiate HOPE's planned national rollup of interventional psychiatry clinics.
This debt facility, combined with proceeds from a previously announced strategic investment, is anticipated to provide a total of $10.3 million in acquisition capital. The funding will support the previously announced acquisitions of Dura Medical, Kadima, and NeuroSpa.
The term sheet anticipates the closing of the first financing tranche by June 19, 2025. Universal Capital, LLC, shares HOPE's vision of building a nationwide network of clinics to address the mental health crisis, with plans to participate in future funding of HOPE transactions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.